Table 4.

Studies of clinical and histopathologic factors predictive of SLN involvement.

Author	Year	N	Institution	Factors Associated with SLN Positivity on Multivariate Analysis
Mraz-Gernhard16	1998	215	Univ. of California	Breslow thickness, ulceration (present), mitotic rate (≥6), ulceration (present), angiolymphatic invasion (present), microsatellites (present)
Nguyen14	2000	112	Medical Univ. of South Carolina	Breslow thickness (>1.5mm), ulceration (present), angiolymphatic invasion (present)
Wagner15	2000	275	Indiana Univ.	Breslow thickness (≥1.25), ulceratioin (present), Mitotic rate (>5)
McMasters13	2001	1058	Sunbelt Melanoma Trial	Breslow thickness, Clark level, ulceration (present), age (≤60)
Rousseau17	2003	1375	MDACC	Breslow thickness, ulceration (present), age (≤50), tumor site (axial)
Sondak5	2004	419	Univ. of Michigan	Breslow thickness, age, mitotic rate (continuous variables)
Wong8	2005	979	MSKCC & Sunbelt Melanoma Trial	Breslow thickness, age, site, Clark level, ulceration
Kruper6	2006	682	Univ. of Pennsylvania	Breslow thickness, mitotic rate (0.1 to 5, >5), TIL (absent)
Mocellin	2006	246	Univ. of Padova, Italy	Breslow thickness, mitotic rate, satellitosis
Sassen18	2007	2303	Sydney Melanoma Unit	Breslow thickness (>2.0mm), age (<40), histology (desmoplastic), ulceration (present).
Taylor19	2007	875	MSKCC	Breslow thickness, ulceration (present), gender (male), TIL (absent)
Paek9	2007	1130	Univ. of Michigan	Breslow thickness, mitotic rate, age (all continuous), site (trunk, leg), angiolymphatic invasion (present)
Niakosari20	2008	96	University of Toronto	Lymphatic invasion (present), age (<50), ulceration (present)
Mandala7	2009	394	Riuniti Hospital, Italy	Breslow thickness, site (axial), TIL (absent)
Mitra21	2010	561	Multiple locations in UK	Breslow thickness, mitotic rate (0.1 to 6, >6), site (H&N, leg, trunk)